Arrowhead director sells 11,600 shares at $87

ARROWHEAD PHARMACEUTICALS, INC.

Rhea-AI Filing Summary

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) director Michael S. Perry reported a sale of 11,600 shares of common stock on 2026-08-18. The price reported is a weighted average of $87.30 per share, with individual trades between $87.20 and $87.44. Following this transaction, he directly holds 111,459 shares, which include previously reported shares underlying Restricted Stock Units, some of which remain subject to vesting conditions. The filing indicates the Rule 10b5-1 trading plan checkbox was not marked.

Insider Trade Summary

Net Seller: 11,600 shares

Net Sell 1 txn

Insider PERRY MICHAEL S

Role Director

Sold 11,600 shs ($1.01M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	11,600	$87.30	$1.01M

Holdings After Transaction: Common Stock — 111,459 shares (Direct)

Footnotes (2)

1. F1. The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $87.20 to $87.44, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
2. F2. Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

Key Figures

Shares sold: 11,600 shares Weighted average sale price: $87.30 per share Sale price range: $87.20–$87.44 per share +1 more

4 metrics

Shares sold 11,600 shares Non-derivative common stock sale on 2026-08-18

Weighted average sale price $87.30 per share Sale of 11,600 shares in multiple transactions

Sale price range $87.20–$87.44 per share Prices for individual trade executions within the reported sale

Shares held after transaction 111,459 shares Direct holdings after the sale, including RSU-related shares

Key Terms

weighted average price, Restricted Stock Units, vesting conditions

3 terms

weighted average price financial

"The price reported on Column 4 is the weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Restricted Stock Units financial

"Includes previously reported shares of common stock underlying Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vesting conditions financial

"a portion of which are still subject to certain vesting conditions."

Vesting conditions are the rules that determine when someone earning company stock or stock options actually gains the right to keep or sell them, typically based on staying with the company for a set time or meeting performance targets. Think of it like keys that unlock gradually — some unlock by calendar date, others only after agreed milestones. Investors care because vesting shapes management incentives, the timing of share sales, and the number of shares that can enter the market, which can affect a company's valuation and ownership mix.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ARWR director Michael S. Perry report?

Michael S. Perry reported selling 11,600 shares of Arrowhead Pharmaceuticals common stock on 2026-08-18 in a transaction coded as a sale of non-derivative securities. After the sale, he directly holds 111,459 shares, including shares underlying Restricted Stock Units.

At what price were the ARWR shares sold in this Form 4 filing?

The reported price is a weighted average of $87.30 per share. The shares were sold in multiple transactions at prices ranging from $87.20 to $87.44, inclusive, as disclosed in the footnote.

How many ARWR shares does Michael S. Perry hold after this sale?

After the reported sale, Michael S. Perry directly holds 111,459 shares of Arrowhead Pharmaceuticals common stock. This amount includes previously reported shares underlying Restricted Stock Units, a portion of which are still subject to vesting conditions.

Does the ARWR Form 4 state that the sale was under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not checked, and the footnotes do not state that the transaction was made under a Rule 10b5-1 trading plan.

What type of security was involved in Michael S. Perry’s ARWR transaction?

The transaction involved Common Stock of Arrowhead Pharmaceuticals as a non-derivative security. The reported sale covered 11,600 shares at a weighted average price of $87.30 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/20/2026 - 05:22 PM Accepted by SEC EDGAR 08/20/2026 - 05:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PERRY MICHAEL S

(Last) (First) (Middle)

177 E. COLORADO BLVD

SUITE 700

(Street)

PASADENA CALIFORNIA 91105

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ARROWHEAD PHARMACEUTICALS, INC. [ ARWR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2026		S		11,600	D	$87.3(1)	111,459(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $87.20 to $87.44, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

2. Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

Remarks:

	/s/Michael Perry	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)